

HB 3380 -1 STAFF MEASURE SUMMARY

House Committee On Behavioral Health and Health Care

Prepared By: Brian Nieubuurt, LPRO Analyst

Meeting Dates: 3/27, 4/4

WHAT THE MEASURE DOES:

Allows physician to prescribe continuous glucose monitor to patient diagnosed with Type I or Type II diabetes that requires treatment with insulin whether or not physician specializes in endocrinology. Requires medical assistance and health insurance to include coverage of continuous glucose monitor prescribed by physician as pharmacy benefit.

ISSUES DISCUSSED:

- Medicaid coverage in other states
- Improvements in diabetes control by individuals with CGM
- Cost savings experienced in other states that require coverage of CGMs

EFFECT OF AMENDMENT:

-1 **Replaces the measure.** Requires medical assistance to include continuous glucose monitor prescribed for recipient under specified circumstances.

FISCAL: Fiscal impact issued

REVENUE: No revenue impact

BACKGROUND:

Continuous glucose monitors (CGMs) continuously monitor a person's blood glucose via a sensor just under the skin, giving real-time updates on those levels via a device that is attached to the person's body. CGMs can make it easier for a person diagnosed with diabetes to track blood glucose levels over time. In its 2015 Oregon Diabetes Report, the Oregon Health Authority's Public Health Division estimated that diabetes affects approximately 287,000 adult Oregonians, or nearly 1 in 10. The prevalence of diabetes has also steadily increased, more than doubling since 1990 and accounting for 3.5 percent of deaths in Oregon in 2012.

According to a 2022 report by the Center for Health Care Strategies, 40 states and the District of Columbia provide some level of Medicaid coverage of CGMs. Twenty states provide coverage as a durable medical equipment (DME) benefit; the other 20 states and the District of Columbia provide coverage a pharmacy benefit.

House Bill 3380 would allow physicians, regardless of specialty, to prescribe continuous glucose monitors to patients diagnosed with Type I or Type II diabetes and require medical assistance and health insurance coverage of the monitors as a pharmacy benefit.